Three years after Pfizer Inc. (NYSE:PFE) dropped a bombshell on its plans to lay off more than 1000 workers. The biopharmaceutical company has come back with some of the best news, on how it plans to use the vacated Groton site. In a joint announcement, Gov. Dannel P. Malloy and Pfizer confirmed that two buildings on the company’s campus will be donated for use in bioscience research as well as act as a storage site for state data. Pfizer Inc. (NYSE:PFE) stock performance was 0.34% in last session and finished the day at $32.40. Traded volume was 20.04million shares in the last session and the average volume of the stock remained 27.15million shares. The beta of the stock remained 0.64. Pfizer Inc. (NYSE:PFE) insider ownership is 0.10%.

Sanofi SA (ADR) (NYSE:SNY) seems to be in for a bumpy ride. On the one hand there is the imminent patent expiry of Lantus in 2015. To put things in perspective, this one drug alone helps generate 17% of Sanofi SA (ADR) (NYSE:SNY) ’s revenue. On the other hand Sanofi SA (ADR) (NYSE:SNY) is expecting encouraging results from final clinical results for its new vaccine against dengue by late September. Sanofi SA (ADR) (NYSE:SNY) rose 0.04 percent to $52.04 Thursday on volume of 8.37million shares. The intra-day range of the stock was $51.81 to $52.22. Sanofi SA (ADR) (NYSE:SNY) has a market capitalization of $138.64billion.

Shares of AbbVie Inc (NASDAQ:ABBV) have received an average rating of “Buy” from the fifteen ratings firms that are presently covering the stock, AmericanBankingNews.com reports. Five research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. AbbVie Inc (NYSE:ABBV)’s stock on Apr 03, 2014 reported a increase of 0.30% to the closing price of $53.50. Its fifty two weeks range is $40.10 -$54.78. The total market capitalization recorded $85.39billion. The overall volume in the last trading session was 6.84million shares. In its share capital, has 1.60billion outstanding shares.

Medical and consumer products giant Johnson & Johnson (NYSE:JNJ) made a big splash this week by agreeing to sell its Ortho-Clinical Diagnostics business to The Carlyle Group (NASDAQ:CG). The diagnostics business, which JNJ founded in 1937, makes blood tests that screen for disease and contributed about 2.6% of JNJ’s revenue last year. On Thursday, shares of Johnson & Johnson (NYSE:JNJ) advanced 0.03% to close the day at $98.26. Company return on investment (ROI) is 15.00% and its monthly performance is recorded as 6.12%. Johnson & Johnson (NYSE:JNJ) quarterly revenue growth is 8.72%.